ABUS - Arbutus Biopharma Corporation

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B (HBV) infection, with its lead pipeline assets including AB-101 (an oral PD-L1 inhibitor) and RNA interference (RNAi) therapeutic candidates targeting HBV. The business model is pre-revenue biotech, relying on licensing royalties from its lipid nanoparticle (LNP) delivery technology platform—which underpins several COVID-19 mRNA vaccines—and partnership/collaboration agreements rather than direct product sales. Revenue is sub-$50M annually, consisting primarily of LNP royalty income and milestone payments, with operations centered in the United States and Canada. Core customers are large pharmaceutical partners and licensees of its LNP delivery technology, not end patients, making it a royalty and licensing business alongside its internal HBV drug development program.

Past Year Trends

• Arbutus and Genevant announced a $2.25 billion global settlement with Moderna on March 3, 2026, resolving all LNP patent infringement actions related to Moderna's COVID-19 vaccine, with Arbutus entitled to approximately $178.7 million (20% share) of the $950 million noncontingent upfront tranche. (Bullish)
• Imdusiran accumulated a total of 10 functional cures in Phase 2a chronic hepatitis B trials and long-term follow-up through Q4 2025, up from 8 patients earlier in the year, including 2 new cures with no interferon in the regimen. (Bullish)
• Cash, cash equivalents, and marketable securities declined from $122.6 million at end-2024 to $91.5 million at end-2025, reflecting $39.6 million in net operating cash burn including one-time restructuring payments during the year. (Bearish)

Next Year Trends

• Moderna's $950 million noncontingent settlement payment is due on or before July 8, 2026, with Arbutus expecting to receive approximately $178.7 million and evaluating a return of capital to shareholders in Q3 2026, which would represent the first meaningful cash distribution in the company's history. (Bullish)
• The FDA's April 2026 Fast Track designation for imdusiran, combined with the ongoing Phase 2b trial initiation in 2025, sets up potential accelerated review milestones and interim data readouts for imdusiran's cHBV program within the next 12 months. (Bullish)
• Arbutus's LNP patent litigation against Pfizer-BioNTech remains unresolved and ongoing as of Q1 2026; a favorable ruling could unlock a settlement or judgment potentially exceeding the Moderna deal given Pfizer's larger COVID-19 vaccine revenue base, but prolonged litigation uncertainty could weigh on valuation. (Bullish)

Red Flags

No severe red flags identified as of August 2025.